In This Article:
MONTPELLIER, France, March 06, 2025--(BUSINESS WIRE)--Regulatory News:
Medincell (Paris:MEDCL):
Pascal Touchon joins the Board of Directors
-
40 years of international experience in the biopharmaceutical industry, holding operational and strategic leadership positions, and serving on the boards of both American and European companies,
-
Former Global Head of Strategy and Business Development then Global Head of the Cell & Gene division at Novartis Oncology, where he led the development and global launch of the world's first approved cell & gene therapy,
-
Currently Chairman of the Board of Atara Biotherapeutics (US), Director at Ipsen, and advisor to Jeito Capital, an investment fund dedicated to biopharmaceutical companies.
This governance evolution is part of an ongoing process to enrich the expertise within the Board of Directors, ensuring robust support for Medincell’s accelerated growth.
Philippe Guy, Chairman of Medincell, said: "Our mission is to define the best strategies to create a lasting impact on global health while continuing to generate value. Strengthening and diversifying expertise within our Board aligns with this goal. Pascal’s international experience, gained within major corporations and biotech companies, will be invaluable in driving innovation at Medincell, fostering new strategic partnerships, and optimizing our organization."
Pascal Touchon, newly appointed Board Member, said: "The Medincell team has proven that it is possible to build a biopharmaceutical company based on innovation and collaboration, creating value for both patients and shareholders. I believe Medincell’s potential is still immense, far beyond what has already been achieved. I’m joining the Board, sharing the ambition of creating even more value while preserving a business model that benefits patients and everyone who contributes to Medincell’s success."
Co-opted by Medincell’s Board of Directors, Pascal Touchon will serve until the next Annual General Meeting, where shareholders will decide on his appointment and a new term.
Sabri Markabi steps away as a Board Member but assumes advisory role
Sabri Markabi said: "It has been an honor and a remarkable journey working with the Medincell teams over the years. Today, patients are benefiting from our technology, and I have no doubt that many more will in the years to come. Reaching this level of maturity is a rare achievement. We can take pride in what we have accomplished and look to the future with confidence."
Philippe Guy said: "Sabri has played a key role as a Board Member during a pivotal period for Medincell. On behalf of the entire team, I sincerely thank him for his valuable contributions. We are delighted to continue benefiting from his expertise."